Sagimet Biosciences Inc (SGMT)
4.10
+0.20
(+4.99%)
USD |
NASDAQ |
May 01, 16:00
4.10
0.00 (0.00%)
After-Hours: 20:00
Sagimet Biosciences Enterprise Value: 29.73M for April 30, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 30, 2024 | 29.73M |
| April 29, 2024 | 40.10M |
| April 26, 2024 | 34.67M |
| April 25, 2024 | 30.21M |
| April 24, 2024 | 38.18M |
| April 23, 2024 | 41.69M |
| April 22, 2024 | 33.72M |
| April 19, 2024 | 33.08M |
| April 18, 2024 | 31.80M |
| April 17, 2024 | 34.99M |
| April 16, 2024 | 38.50M |
| April 15, 2024 | 50.63M |
| April 12, 2024 | 59.25M |
| April 11, 2024 | 71.69M |
| April 10, 2024 | 66.59M |
| April 09, 2024 | 74.57M |
| April 08, 2024 | 76.80M |
| April 05, 2024 | 74.57M |
| April 04, 2024 | 79.03M |
| April 03, 2024 | 78.40M |
| April 02, 2024 | 72.33M |
| April 01, 2024 | 72.01M |
| March 28, 2024 | 78.08M |
| March 27, 2024 | 87.97M |
| March 26, 2024 | 72.01M |
| Date | Value |
|---|---|
| March 25, 2024 | 71.69M |
| March 22, 2024 | 49.03M |
| March 21, 2024 | 53.50M |
| March 20, 2024 | 50.63M |
| March 19, 2024 | 48.08M |
| March 18, 2024 | 33.40M |
| March 15, 2024 | 34.04M |
| March 14, 2024 | 42.97M |
| March 13, 2024 | 53.42M |
| March 12, 2024 | 64.26M |
| March 11, 2024 | 79.89M |
| March 08, 2024 | 88.50M |
| March 07, 2024 | 110.83M |
| March 06, 2024 | 117.85M |
| March 05, 2024 | 98.07M |
| March 04, 2024 | 104.45M |
| March 01, 2024 | 97.12M |
| February 29, 2024 | 100.62M |
| February 28, 2024 | 108.92M |
| February 27, 2024 | 140.81M |
| February 26, 2024 | 134.75M |
| February 23, 2024 | 116.25M |
| February 22, 2024 | 119.76M |
| February 21, 2024 | 120.08M |
| February 20, 2024 | 127.74M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-50.78M
Minimum
Nov 13 2023
342.49M
Maximum
Aug 03 2023
117.94M
Average
74.57M
Median
Apr 05 2024
Enterprise Value Benchmarks
| Madrigal Pharmaceuticals Inc | 3.541B |
| 89bio Inc | 256.29M |
| Viking Therapeutics Inc | 7.811B |
| Akero Therapeutics Inc | 846.32M |
| Arrowhead Pharmaceuticals Inc | 2.597B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.151M |
| Total Expenses (Quarterly) | 9.466M |
| EPS Diluted (Quarterly) | -0.356 |
| Earnings Yield | -31.93% |